EUVIMEDEUVIMED entdecken
Leitlinie

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1

Mary-Ellen Taplin, Irbaz Bin Riaz iD, R Bryan Rumble iD, Syed Arsalan Ahmed Naqvi, Thomas A Hope iD, Mariane Fontes Dias iD, Huan He, Sebastien J Hotte iD, Hamid Emamekhoo iD, M Hassan Murad iD, Paul Celano, Terry M Kungel und 3 weitere

Journal of Clinical Oncology · 20.02.2026 · 44 (6)

DOI: 10.1200/jco-25-02693 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.02.2026. Verfasst von Mary-Ellen Taplin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 ). Updates are published regularly and can be found at www.asco.org/genitourinary-cancer-guidelines .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantHumansMaleNeoplasm MetastasisPractice Guidelines as Topic

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston, MA.
  • Mayo Clinic, Phoenix, AZ.
  • American Society of Clinical Oncology, Alexandria, VA.
  • University of California San Francisco, San Francisco, CA.
  • Oncoclinicas&Co-Medica Scientia Innovation Research (MEDSIR), Latin America Cooperative Group (LACOG)-Genito-Urinary, Rio de Janeiro, Brazil.
  • Yale University, New Haven, CT.

ORCID-Profile: Irbaz Bin Riaz, R Bryan Rumble, Thomas A Hope, Mariane Fontes Dias, Sebastien J Hotte, Hamid Emamekhoo, M Hassan Murad, Michael Thomas Serzan, Rahul A Parikh

Zitieren

APA

Taplin, M. E., Riaz, I. B., Rumble, R. B., Naqvi, S. A. A., Hope, T. A., Dias, M. F., He, H., Hotte, S. J., Emamekhoo, H., Murad, M. H., Celano, P., Kungel, T. M., Hentzen, S., Serzan, M. T., & Parikh, R. A. (2026). Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1. Journal of Clinical Oncology, 44(6). https://doi.org/10.1200/jco-25-02693

Vancouver

Taplin ME, Riaz IB, Rumble RB, Naqvi SAA, Hope TA, Dias MF, et al. Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1. Journal of Clinical Oncology. 2026;44(6). doi:10.1200/jco-25-02693

BibTeX
@article{Taplin2026,
  author = {Taplin, Mary-Ellen and Riaz, Irbaz Bin and Rumble, R Bryan and Naqvi, Syed Arsalan Ahmed and Hope, Thomas A and Dias, Mariane Fontes and He, Huan and Hotte, Sebastien J and Emamekhoo, Hamid and Murad, M Hassan and Celano, Paul and Kungel, Terry M and Hentzen, Steve and Serzan, Michael Thomas and Parikh, Rahul A},
  title = {Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {6},
  doi = {10.1200/jco-25-02693}
}
Kostenlos starten →